Comprehensive treatment of unresectable cardiac angiosarcoma: A case report and review of literature

Abstract

Abstract. Cardiac angiosarcoma is a rare but lethal tumor that is difficult to diagnose and treat, due to its rapid local relapse and high incidence of systemic metastasis. The prognosis of cardiac angiosarcoma is dismal, with a mean life expectancy of only a few months. We herein report a case of unresectable angiosarcoma arising from the right atrium. The patient received first-line chemotherapy with weekly paclitaxel, and second-line therapy with vinorelbine and bevacizumab upon disease progression. The progression-free survival was 6 months and the overall survival was 7 months. The patient eventually succumbed to respiratory failure. A study of the present case and a review of the relevant literature suggest that treatment decisions for unresectable locally advanced or metastatic cardiac angiosarcoma are difficult, as the published literature on this disease mainly consists of case reports without sufficient data. Therefore, further clinical trials specific to the treatment of unresectable cardiac angiosarcoma are warranted.

Right atrial cardiac angiosarcoma treated with concurrent proton beam therapy and paclitaxel: A novel approach to a rare disease

“…Previously, the concurrent use of chemotherapy and RT to treat cardiac sarcomas has been described in small case reports 1 . Only one report of a patient with undifferentiated pleomorphic sarcoma of the left atrium has been reported to receive PBT alone to the primary tumor during one of the many relapses 2 .…”

Cadonilimab plus anlotinib effectively relieve rare cardiac angiosarcoma with multiple metastases: a case report and literature review

“…No unified standard for AS chemotherapy currently exists, but research suggests that cytotoxic drugs such as platinum, doxorubicin, paclitaxel, and methotrexate may benefit patients not eligible for radical surgery [ 22 ]. Advancements in oncology and immunology have led to the emergence of tumor immunotherapy as an anti-tumor approach, complementing surgery, radiotherapy, and chemotherapy [ 23 ]. A study analyzing 106 cutaneous AS cases found a correlation between PD-1/PD-L1 expression and AS progression, suggesting that anti-PD-1 antibody therapy could be a potential novel treatment [ 24 ].…”